SCHEMBL3368130

SCHEMBL3368130

C=CS(=O)(=O)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)N(Cc1ccccc1)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.43
ANPEP P15144 2/20 0.42
CTSL P07711 1/20 0.41
MMP1 P03956 4/20 0.41
MMP9 P14780 3/20 0.41
MMP8 P22894 3/20 0.41
MMP2 P08253 2/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
MMP13 P45452 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MMP3 P08254 3/20 0.40
PSMB1 P20618 1/20 0.40
PSMB5 P28074 1/20 0.40
PSMB2 P49721 1/20 0.40
MME P08473 2/20 0.40
MMP14 P50281 1/20 0.39
MMP7 P09237 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2246262 0.88 MME (0.47) ALDH1A1ANPEPCTSLMMP1MEN1
SCHEMBL4968073 0.81 MME (0.59) CTSLMMP1MMP9MMP8MMP2
SCHEMBL6465336 0.81 PSMB1 (0.49) ALDH1A1ANPEPCTSLMMP1MMP9
SCHEMBL30450002 0.81 PSMB1 (0.49) ALDH1A1ANPEPCTSLMMP1MMP9
SCHEMBL25259821 0.81 PSMB1 (0.49) ALDH1A1ANPEPCTSLMMP1MMP9
SCHEMBL3172719 0.79 CTSK (0.64) CTSLPSMB1PSMB5PSMB2
Carbamic Acid SCHEMBL30450803 0.78 CAPN1 (0.48) ALDH1A1ANPEPCTSLMMP1MMP3
SCHEMBL4972640 0.78 MMP9 (0.44) ANPEPCTSLMMP1MMP9MMP8
SCHEMBL20741006 0.77 CTSK (0.48) ALDH1A1ANPEPCTSLMMP1MMP9
SCHEMBL20741008 0.77 CTSK (0.48) ALDH1A1ANPEPCTSLMMP1MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050250702-A1 Controlling availability or activity of proteins by use of protease inhibitors or receptor fragments RECHARGE B.V. (NL) 2005-11-10 US claimed
EP-1062243-A2 CONTROLLING AVAILABILITY OR ACTIVITY OF PROTEINS BY USE OF PROTEASE INHIBITORS OR RECEPTOR FRAGMENTS Universiteit Utrecht (NL) 2000-12-27 EP claimed
EP-0943624-A1 Peptidic inhibitors of down-regulation of growth hormone receptor Universiteit Utrecht (NL) 1999-09-22 EP claimed
WO-1999046298-A2 CONTROLLING AVAILABILITY OR ACTIVITY OF PROTEINS BY USE OF PROTEASE INHIBITORS OR RECEPTOR FRAGMENTS UNIVERSITEIT UTRECHT (NL) 1999-09-16 WO claimed
EP-1062243-B1 CONTROLLING AVAILABILITY OR ACTIVITY OF PROTEINS BY USE OF PROTEASE INHIBITORS OR RECEPTOR FRAGMENTS RECHARGE B V (NL) 2010-01-06 EP disclosed
EP-0912601-B2 SUPPRESSION OF IMMUNE RESPONSE VIA INHIBITION OF CATHEPSIN S MASSACHUSETTS INST TECHNOLOGY (US) 2008-11-05 EP disclosed
US-7427591-B2 Suppression of immune response via inhibition of cathepsin S MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2008-09-23 US disclosed
US-7285525-B2 Suppression of immune response via inhibition of cathepsin S MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2007-10-23 US disclosed
US-20050250702-A1 Controlling availability or activity of proteins by use of protease inhibitors or receptor fragments RECHARGE B.V. (NL) 2005-11-10 US disclosed
US-20050095248-A1 Suppression of immune response via inhibition of cathepsin S MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2005-05-05 US disclosed
US-20050080010-A1 Suppression of immune response via inhibition of cathepsin S NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-04-14 US disclosed
US-6855546-B1 Controlling availability or activity of proteins by use of protease inhibitors or receptor fragments UNIVERSITEIT UTRECHT (NL) 2005-02-15 US disclosed
EP-0912601-B1 SUPPRESSION OF IMMUNE RESPONSE VIA INHIBITION OF CATHEPSIN S MASSACHUSETTS INST TECHNOLOGY (US) 2003-11-26 EP disclosed
US-20030166534-A1 Suppression of immune response via inhibition of cathepsin S MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2003-09-04 US disclosed
US-6608030-B1 Suppression of immune response via inhibition of cathepsin S BRIGHAM & WOMEN'S HOSPITAL, INC. 2003-08-19 US disclosed
EP-1062243-A2 CONTROLLING AVAILABILITY OR ACTIVITY OF PROTEINS BY USE OF PROTEASE INHIBITORS OR RECEPTOR FRAGMENTS Universiteit Utrecht (NL) 2000-12-27 EP disclosed
EP-0943624-A1 Peptidic inhibitors of down-regulation of growth hormone receptor Universiteit Utrecht (NL) 1999-09-22 EP disclosed
WO-1999046298-A2 CONTROLLING AVAILABILITY OR ACTIVITY OF PROTEINS BY USE OF PROTEASE INHIBITORS OR RECEPTOR FRAGMENTS UNIVERSITEIT UTRECHT (NL) 1999-09-16 WO disclosed
EP-0912601-A1 SUPPRESSION OF IMMUNE RESPONSE VIA INHIBITION OF CATHEPSIN S MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1999-05-06 EP disclosed
WO-1997040066-A1 SUPPRESSION OF IMMUNE RESPONSE VIA INHIBITION OF CATHEPSIN S MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1997-10-30 WO disclosed